TrialBritish journal of cancer2014

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.

D Generali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.